Mobile website
Clinical Research
Rituximab combined with routine chemotherapy in treatment of B-cell lymphoma: A Meta analysis of randomized controlled trials
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective:To systematically assess the efficacy and safety of rituximab combined with routine chemotherapy in the treatment of B-cell lymphoma by Meta-analysis. Methods: We searched Embase, Pubmed, the Cochrane Library, VIP, CNKI, and CBM literature databases for randomized controlled trials (RCTs) of rituximab combined with routine chemotherapy in the treatment of B-cell lymphoma. Two reviewers independently assessed the quality of the included studies and extracted the data. The data were analyzed by Review Manager software (version 5.0). Results: Ten RCTs were finally included in the present analysis, and the results showed that rituximab combined with routine chemotherapy improved the overall survival rate (HR=0.64, 95% CI \[0.53, 0.77\]) and overall response rate (RR=1.21, 95% CI \[1.11, 1.32\]) of B-cell lymphoma patients compared with routine chemotherapy. There was no statistical difference between the two groups in 3/4 grade infection, 3/4 grade thrombocytopenia, with the relative risk being 1.15 (0.58, 230) and 1.04 (0.71, 1.52), respectively. There was significant difference in 3/4 grade granulocytopenia, 3/4 grade granulocytopenia, 3/4 grade leukocytopenia, and 3/4 grade fever, with the relative risk being 1.16 (1.02, 1.31), 1.31 (112, 153) and 349 (1.56, 778), respectively. Conclusion: Rituximab combined with routine chemotherapy can improve the overall survival rate and overall response rate of B-cell lymphoma patients, but results in a higher incidence of 3/4 grade granulocytopenia, 3/4 grade granulocytopenia, 3/4 grade leukocytopenia, and 3/4 grade fever.
Keywords:
Project Supported:
Clc Number:
